Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Race Oncology Ltd. ( (AU:RAC) ).
Race Oncology Ltd has made significant strides in its clinical development efforts, as highlighted in their quarterly report. Key achievements include progress in the Phase 1 trial of their drug RC220 in combination with doxorubicin, with the first patient treatment expected in Q1 2025. The company also strengthened its board with the appointment of Dr. Megan Baldwin as an Independent Non-Executive Director, bringing her extensive experience in oncology drug development. Financially, Race received an R&D Tax Incentive payment, boosting their cash reserves to $18.78 million, which supports their ongoing research and development activities.
More about Race Oncology Ltd.
Race Oncology Ltd is a biotechnology company primarily engaged in the development of cancer therapeutics, focusing on innovative treatments for advanced solid tumors using bisantrene as a key compound. The company is advancing its drug pipeline through clinical trials and collaborations with research institutions.
YTD Price Performance: -10.0%
Average Trading Volume: 82,436
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$213.7M
Find detailed analytics on RAC stock on TipRanks’ Stock Analysis page.
